To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min "I believe we rarely regret the ...

Gilead is hoping to break ground early next year on its Chess Hatch campus as part of its plans to expand its presence in Foster City. The company has been headquartered in Foster City for years, and ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The development, in the works ...

Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results driving optimism for continued growth. Gilead Sciences' key growth drivers include robust sales from Livdelzi and ...

– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. – The funding focuses on reducing barriers to fresh food in vulnerable communities ...

Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the positions showed up on publicly ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option.

Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...